Clinical Trials
33 trialsPTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Immune Checkpoint Inhibitor Combined With Pemetrexed Intrathecal Injection for Leptomeningeal Metastasis From Solid Tumors
Guangzhou Medical University
Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases
Icahn School of Medicine at Mount Sinai
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
Sun Yat-sen University
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Icahn School of Medicine at Mount Sinai
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer
Tianjin Medical University Cancer Institute and Hospital
Study of JS004 Combined With Toripalimab for Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Immunotherapy Rechallenge in Patients with Solid Tumors in Clinical Trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
FD-IMPACT
Fudan University
Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Safety and Efficacy of RX-af01 Combined With PD-1 Antibody
Sun Yat-sen University
Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer
Shouyao Holdings (Beijing) Co. LTD
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Thermal Ablation Followed by Immunotherapy for HCC
Xiangya Hospital of Central South University
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
Xijing Hospital
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
Sun Yat-sen University
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
Peking University
Toripalimab
Shanghai Zhongshan Hospital
ATG-008 Combined With Toripalimab in Advanced Solid Tumors
Sichuan University
CT32
Shanghai Junshi Bioscience Co., Ltd.
JSFOL
Xiangya Hospital of Central South University
CCRT+PD-1
Peking University Third Hospital
STUHCCPVTT
Sichuan University
Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ
Peking University